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Abstract Tocilizumab, a humanized monoclonal anti-
body to the interleukin 6 (IL-6) receptor, was approved for
use as rheumatoid arthritis (RA) therapy in Japan in 2008,
but its efﬁcacy and tolerability in daily practice has not yet
been reported. We report the results of a multicenter ret-
rospective study on the efﬁcacy and safety of tocilizumab
involving all patients (n = 229) who were started on toc-
ilizumab therapy at three rheumatology institutes in Japan
from April 2008 through to March 2009. Tocilizumab was
infused every 4 weeks at a dose of 8 mg/kg according to
the drug labeling. Among the 229 patients, 55% concom-
itantly received methotrexate (MTX) and 63% had previ-
ously received anti-tumor necrosis factor (TNF) therapy.
Average disease activity score (DAS) 28 of all 229 patients
signiﬁcantly decreased from 5.70 to 3.25 after 24 weeks of
therapy. A European League Against Rheumatism (EULAR)
good response and DAS28 remission was achieved in 57.4
and 40.7% of the patients, respectively, at 24 weeks. White
blood cell counts signiﬁcantly decreased and liver enzymes
and total cholesterol slightly but signiﬁcantly increased;
however, liver enzyme levels did not increase in patients
without MTX. Tocilizumab was discontinued in 47 cases
(20.5%) due to lack of efﬁcacy (5.2%), adverse events
(11.4%), and other reasons (3.9%). The overall retention rate
at 24 weeks was 79.5%. Based on these results, we conclude
that tocilizumab therapy in daily rheumatology practice
appears to be highly efﬁcacious and well tolerated among
activeRApatients,includingtheanti-TNFtherapy-refractory
population. Tocilizumab infusion is therefore applicable not
onlyasanalternativeapproachforanti-TNFtherapy-resistant
patients, but also as primary biologic therapy for active RA
patients.
Keywords Rheumatoid arthritis  Tocilizumab  IL-6 
Remission  Retrospective study
Introduction
The introduction of biologic agents into the rheumatoid
arthritis (RA) treatment landscape has altered both thera-
peutic strategies as well as patient outcomes [1–3]. Indeed,
the aim of medical treatment of RA patients has shifted
from the short-term improvement of the quality of life
(QOL) through pain relief to the long-term improvement of
QOL by the prevention of joint damage and improved
mortality. Tumor necrosis factor (TNF) is considered to be
a major cytokine involved in RA pathogenesis, and anti-
TNF therapy using monoclonal antibodies or fusion pro-
teins was the ﬁrst anti-cytokine therapy to be developed for
RA [4–6]. Anti-TNF therapy has achieved great success in
suppressing rheumatoid inﬂammation and preventing the
progression of joint damage in RA patients [7–9], thereby
conﬁrming that TNF indeed appears to be critically
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TNF is not the only cytokine involved in RA pathogenesis,
and several candidate cytokines represent potential thera-
peutic targets for anti-cytokine therapy. Interestingly, the
interleukin 1 (IL-1) receptor antagonist anakinra did not
demonstrate a signiﬁcant therapeutic effect in the treatment
of RA [10], even though IL-1 is believed to be involved
in the pathogenesis of RA synovitis [11], leading to the
conclusion that not all cytokines are necessarily successful
therapeutic targets for RA anti-cytokine therapy.
Tocilizumab, a monoclonal antibody directed against
the IL-6 receptor, was developed in Japan through a col-
laborative effort of Osaka University and Chugai Phar-
maceutical Co. (Tokyo, Japan) [12]. After a series of
carefully conducted preclinical studies, tocilizumab was
evaluated in RA patients, in whom it demonstrated prom-
ising efﬁcacy [13–15]. The efﬁcacy of tocilizumab was
assessed in several different patient groups in both Japan
and Western countries, and it has been shown to improve
the signs and symptoms of RA patients, to suppress the
radiological progression of joint damage [16], and to
improve the QOL and physical disability [17]. However,
the utility of tocilizumab has not been well documented in
daily clinical practice outside of the clinical trial setting.
Tocilizumab was ﬁrst approved as a therapy for RA in
Japan in April 2008, and approximately 9,000 Japanese RA
patients had received tocilizumab by the end of 2009.
Although, as mentioned above, the efﬁcacy and safety of
tocilizumab have been well established in several ran-
domized control trials (RCTs), given the differences
between the patient populations that participate in RCTs
versus those treated in clinical practice, it is also necessary
to evaluate the efﬁcacy and safety of this agent in the daily
clinical rheumatology practice setting. We have therefore
conducted a retrospective study of tocilizumab use in daily
rheumatology practice in three rheumatology institutes in
Japan and analyzed factors potentially associated with
tocilizumab efﬁcacy. Here, we describe the clinical proﬁles
of RA patients seen in daily rheumatology practice during
the ﬁrst 6 months of tocilizumab treatment.
Patients and methods
Patients
The study cohort consisted of all RA patients (n = 229)
who fulﬁlled the classiﬁcation criteria of the American
College of Rheumatology [18] and who had undergone
tocilizumab treatment between April 2008 (following for-
mal approval of tocilizumab for RA) up to March 2009 at
one of three major rheumatology centers in Japan: (1) the
Institute of Rheumatology of the Tokyo Women’s Medical
University, (2) the First Department of Internal Medicine
of the School of Medicine, University of Occupational &
Environmental Health Japan, Kitakyushu, or (3) the Divi-
sion of Rheumatology and Clinical Immunology, Depart-
ment of Internal Medicine, Saitama Medical Center,
Saitama Medical University, Saitama. All data on these
patients were evaluated retrospectively.
Demographic data, including disease duration and
concomitant therapy, were collected from medical charts.
The following parameters were evaluated at 24 weeks after
the initial tocilizumab infusion: patient-recorded 28 tender
joint counts (TJC), patient-recorded 28 swollen joint count
(SJC), patient’s global assessment of disease activity
[patient’s general health (GH)], erythrocyte sedimentation
rate (ESR), and C-reactive protein (CRP) level.
Tocilizumab therapy
Tocilizumab wasinfused every 4 weeks ata dose of8 mg/kg
according to the drug labeling and the Japan College of
Rheumatology guidelines for tocilizumab therapy [19].
Concomitant use of methotrexate (MTX) was at the dis-
cretion of the attending physician.
Therapeutic response
Disease activity was assessed by Disease Activity Score
(DAS) 28-ESR and DAS28-CRP calculated using standard
formulas [20]. Disability was assessed by the Health
Assessment Questionnaire Disability Index (HAQ-DI)
using the original HAQ [21] or the Japanese version of
HAQ [22]. The primary clinical efﬁcacy endpoint was the
decrease in DAS28-ESR from baseline to week 24; sec-
ondary endpoints included decreases in DAS28-CRP and
HAQ. Response to tocilizumab therapy was also evaluated
using the European League Against Rheumatism (EULAR)
response criteria [23]. Changes in laboratory data were also
evaluated.
Discontinuation of tocilizumab treatment
Cases in which tocilizumab therapy was discontinued
were further analyzed and the causes of discontinuation
evaluated.
Statistical analysis
Patient baseline characteristics were summarized using
mean, standard deviation (SD), median, and percentiles for
the overall patient population and for patient subgroups
deﬁned by the concomitant use of MTX and prior use of
anti-TNF agents. The primary endpoint was assessed by a
t test. The secondary endpoints and subgroup differences of
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observations carried forward (LOCF) method was applied
to evaluate efﬁcacy in a valid manner because data could
not be obtained from patients who discontinued toc-
ilizumab therapy. Logistic regression was used for the
exploratory analysis to identify variables associated with
an EULAR good response and remission at 24 weeks as
deﬁned by DAS28-ESR. All reported P values are two-
sided and not adjusted for multiple testing. P values\0.05
were considered to indicate statistical signiﬁcance for the
primary endpoint. Data were analyzed with R ver. 2.9.
Results
Demographic data of patients from the three institutes
Baseline characteristics of the 229 patients who received
tocilizumab therapy at the three rheumatology institutes
in Japan from the time of its formal authorization for use in
RA through to the end of March 2009 are shown in
Table 1. Overall, 55% of patients concomitantly received
MTX, while 63% had previously received anti-TNF ther-
apy prior to tocilizumab; thus, the baseline characteristics
of patients who did/did not concomitantly receive MTX
and who did/did not receive prior anti-TNF therapy are also
shown in Table 1. Prior biologic agents administered
before entry into the study included inﬂiximab (85/229
cases; 37%), etanercept (94; 41%), and adalimumab (4;
2%). The baseline data of patients who did and did not
previously receive biologic therapy were not very different;
however, the data of patients who did and did not receive
concomitant MTX substantially differed. Patients who did
not receive MTX had a longer disease duration, higher
disease activity, and a lower incidence of previous use of
anti-TNF agents. It should be noted that the average dose
of MTX (8.73 mg/week) was relatively low compared to
that administered in Western countries, since there is an
ofﬁcial regulation concerning the maximum dose of MTX
in Japan [24].
Efﬁcacy of tocilizumab
Clinical efﬁcacy was evaluated by DAS28-ESR, DAS28-
CRP, EULAR response criteria, and HAQ-DI. Among all
229 patients, DAS28-ESR decreased from 5.70 ± 1.24
(mean ± SD) to 3.25 ± 1.62, DAS28-CRP decreased from
4.96 ± 1.19 to 0.87 ± 1.41, and HAQ-DI decreased from
1.58 ± 0.79 to 1.33 ± 0.87 at week 24 of treatment,
demonstrating a signiﬁcant improvement in these three
clinical parameters (P\0.0001). Figure 1 illustrates the
decrease of the DAS28-ESR and its components (TJC, SJC,
ESR, and GH) together with CRP. Although the decreases
were signiﬁcant for all clinical markers, the decreases in
CRP and ESR were the most striking. The decrease in GH
was statistically signiﬁcant, but to a lesser degree than that
of the other parameters.
The efﬁcacy of tocilizumab was assessed in patients
who did and did not receive concomitant MTX (Fig. 2).
The mean DAS28-ESR and HAQ-DI values for patients
with concomitant MTX use (n = 127) were 5.51 ± 1.16
and 1.44 ± 0.74, respectively, at baseline and 2.89 ± 1.50
and 1.14 ± 0.78, respectively, at 24 weeks. However, the
DAS28 and HAQ-DI values of patients who did not
receive concomitant MTX (n = 102) were 5.94 ± 1.30
and 1.75 ± 0.82, respectively, at baseline and 3.71 ± 1.67
and 1.58 ± 0.92, respectively, at 24 weeks (Fig. 2b, e). At
all time points after week 4, DAS28-ESR, DAS28-CRP,
and HAQ-DI values were signiﬁcantly lower in patients
who concomitantly received MTX (P\0.0001).
The efﬁcacy of tocilizumab therapy was also compared
between patients who did and did not previously receive
anti-TNF therapy. Mean DAS28-ESR and HAQ-DI values
in patients who previously received anti-TNF therapy
(n = 144) were 5.72 ± 1.25 and 1.54 ± 0.75, respec-
tively, at baseline and 3.21 ± 1.60 and 1.30 ± 0.83,
respectively, at 24 weeks; in contrast, patients who did not
previously receive anti-TNF therapy (n = 85) had values
of 5.66 ± 1.22 and 1.64 ± 0.85, respectively, at baseline
and 3.33 ± 1.67 and 1.39 ± 0.94, respectively, at 24 weeks
(Fig. 2c, f). At all time points, no differences were observed
between patients who did and did not previously receive
anti-TNF therapy.
The proportions of patients who had high disease
activity, moderate disease activity, low disease activity,
and remission as assessed by the DAS28-ESR were 67.9,
30.4, 0.9, and 0.9%, respectively, at baseline, and 14.6,
31.4, 13.3, and 40.7%, respectively, at 24 weeks (Fig. 3).
EULAR responses at 24 weeks were good in 57.4% of
patients, moderate in 30.6% of patients, and absent in
12.0% of patients, as assessed by the DAS28-ESR.
Changes of categorized disease activity were compared
between patients who did and did not receive concomitant
MTX. Superior efﬁcacy was observed in patients who
received concomitant MTX; remission rates by the DAS28
(\2.6) were 40.7% in the total patient population, 49.2% in
patients who received concomitant MTX, and 30.0% in
patients who did not receive concomitant MTX. In con-
trast, while changes in categorized disease activity were
also compared between patients who did and did not pre-
viously receive anti-TNF therapy, no differences were
noted.
Similarly, response to tocilizumab as determined by the
EULAR response criteria was compared between patients
who did and did not receive concomitant MTX and
between patients who did and did not previously receive
124 Mod Rheumatol (2011) 21:122–133
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123anti-TNF therapy. While higher efﬁcacy was observed in
patients who received concomitant MTX, prior use of anti-
TNF agents did not appear to inﬂuence the EULAR
response.
Demographic factors related to clinical efﬁcacy
of tocilizumab
Logistic regression analysis of factors associated with a
good EULAR response at 24 weeks (n = 120) versus
moderate or no response (n = 89) was conducted using
gender, age, disease duration, prior use of anti-TNF agent,
MTX dose, prednisolone dose, HAQ at baseline and
DAS28 at baseline as explanatory variables. The analysis
revealed that younger age was independently associated
with a good EULAR response.
Similarly, the same analysis of factors associated with
remission at 24 weeks (n = 92) versus no remission
(n = 137) indicated that younger age and lower DAS28
values were independently associated with remission. No
other factors appeared to have a statistically signiﬁcant
predictive value for remission.
Laboratory data after initiation of tocilizumab
Laboratory data were regularly monitored throughout the
24 weeks of tocilizumab therapy (Table 2). In terms of
those laboratory values used to measure disease activity,
CRP levels, ESR, and matrix metalloproteinase-3 (MMP-3)
levels had signiﬁcantly decreased by 24 weeks, while
hemoglobin (Hb) levels had signiﬁcantly increased.
With respect to laboratory parameters used to monitor
safety, total cholesterol (TC) levels and liver enzyme
[aspartate aminotransferase (AST) and alanine amino-
transferase (ALT)] levels slightly but signiﬁcantly
increased, while white blood cell (WBC) counts signiﬁ-
cantly decreased. However, liver enzyme levels did not
increase signiﬁcantly in patients who did not concomitantly
receive MTX. No clinically relevant safety ﬁndings were
reported even in patients with elevated liver enzyme levels.
Discontinuation of tocilizumab therapy
A Kaplan–Meier plot of tocilizumab discontinuation is
shown in Fig. 4. Tocilizumab was discontinued during the
Fig. 1 Efﬁcacy of tocilizumab infusion in inhibiting the signs and
symptoms of rheumatoid arthritis (RA) patients seen in daily clinical
practice. Values of the Daily Activity Score based on 28 joints
(DAS28; a) and its components [tender joint count (TJC; b), swollen
jointcount(SJC; c),goodhealth(GH;d),anderythrocytesedimentation
rate (ESR; e)] together with C-reactive protein (CRP) levels (f)f r o m
baseline to 24 weeks after the initiation of tocilizumab therapy are
shown. Data were analyzed by the last observations carried forward
(LOCF)method.Valuesweresigniﬁcantlylower than baseline valuesat
all time points after 4 weeks of treatment (P\0.00001)
126 Mod Rheumatol (2011) 21:122–133
12324-week observation period in 47 (20.5%) of the 229
patients due to a lack of efﬁcacy (12 patients, 5.2%),
adverse events (26 patients, 11.4%), and other reasons (9
patients, 3.9%)—and continued in 79.5% of patients. The
retention rate at 24 weeks was 80.8% in patients who
concomitantly received MTX, 74.4% in those who did not
concomitantly receive MTX (P = 0.197 by log-rank test),
77.6% in those who previously received anti-TNF therapy,
and 78.5% in those who did not previously receive anti-
TNF therapy (P = 0.892 by log-rank test). Adverse events
responsible for the discontinuation of tocilizumab included
six cases of pneumonia, three cases of cardiac failure and
concomitant disease aggravation, two cases of hepatic
failure (liver enzyme elevation), interstitial pneumonia,
skin ulcer and cerebral hemorrhage, and one case of ana-
phylaxis, chest pain, myocardial infarction, breast cancer,
leucopenia, and phlegmon (Table 3).
Discussion
This study was conducted to determine the efﬁcacy of
tocilizumab therapy and to identify other factors associated
with the effectiveness of tocilizumab therapy in Japanese
RA patients receiving treatment in a university hospital
outpatient setting at three rheumatic disease institutions.
A study of the efﬁcacy of tocilizumab in daily practice in
a study group in the Kyushu area demonstrated the sig-
niﬁcant efﬁcacy of this new biologic [25]. Many investi-
gator-oriented studies of tocilizumab are currently being
conducted in Japan, and more data should be available in
the near future.
During the study period, only three anti-TNF therapies
(inﬂiximab, etanercept, and adalimumab) were available to
treat RA in Japan; no other biologic agents, including
abatacept and rituximab, was available. Tocilizumab was
Fig. 2 Efﬁcacy of tocilizumab infusion in inhibiting the signs and
symptoms of RA patients in daily clinical practice. Values of DAS28
(a–c) and HAQ-DI (d–f) from baseline to 24 weeks after initiation of
tocilizumab therapy are shown: a, d all 229 cases, b, e patients who
concomitantly received methotrexate (MTX; ﬁlled diamond,
n = 127) or did not receive MTX (ﬁlled square, n = 102), c,
f patients who previously received anti-tumor necrosis factor (TNF)
therapy (ﬁlled diamond, n = 144) or did not previously receive anti-
TNF therapy (ﬁlled square, n = 85). Data were analyzed by the
LOCF method. a, d At all time points after 4 weeks, values are
signiﬁcantly decreased from baseline (P\0.00001), b, e at all time
points after 4 weeks, values of patients who concomitantly received
MTX are signiﬁcantly lower than those of patients who did not
(P\0.00001), c, f at all timepoints after 4 weeks, values did not
differ between patients who did and did not previously receive anti-
TNF therapy
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123ﬁrst approved in Japan in April 2008, and results from
clinical studies on its efﬁcacy and safety in RA patients
seen in daily rheumatology practice outside the clinical
trial setting are quite important for evaluation purposes.
All of the patients enrolled in this study were essentially
MTX-resistant, two-thirds were anti-TNF therapy-resistant,
and the average DAS28 at baseline was 5.70. Conse-
quently, these patients had severe RA. Based on our results,
tocilizumab therapy was highly efﬁcacious in these RA
patients seen in daily clinical practice, and the overall
remission rate at 24 weeks was as high as 40.7%.
It is difﬁcult to compare efﬁcacy in clinical studies with
strict inclusion and exclusion criteria to that observed in
daily clinical practice. The Japan College of Rheumatology
provides a guideline for tocilizumab use [19] to which most
rheumatologists comply; however, the regulations of this
guideline are much less stringent compared to the inclusion
and exclusion criteria of clinical studies. Even after these
differences are taken into consideration, the efﬁcacy of
tocilizumab demonstrated in our study is comparable to or
even higher than those reported in clinical studies. The
remission rates in our study were 40.7% in the overall
study population, 49.2% in patients who concomitantly
received MTX, and 30.0% in patients who did not con-
comitantly receive MTX, while remission rates in previ-
ously reported clinical studies ranged from 27% in the
OPTION study [17] to 59% in the SAMURAI study [10].
The tocilizumab-induced remission rate in the SAMURAI
study was remarkably high, most likely because this study
was conducted in early RA patients whose average disease
duration was 2 years [10]. In contrast, the average disease
duration of patients in our study was 12.4 years. Since
tocilizumab directly reduces acute-phase reactants, such as
CRP and ESR [26], it is not surprising that decreases in the
ESR and CRP levels were among the most prominently
changed DAS28 components, as shown in Fig. 1. How-
ever, other factors, including TJC, SJC, and GH, were also
signiﬁcantly decreased; thus, the higher remission rates
observed in this study must not have been solely dependent
on the potent suppression of acute-phase reactants by
tocilizumab.
Concomitant use of MTX resulted in a rapid and sus-
tained response to tocilizumab, even though the average
MTX dose was relatively low (average at baseline: 8.7 mg/
week) compared to that used in Western countries. Gov-
ernment regulations have limited the maximum dose of
MTX to 8 mg/week in Japan; however, many rheumatol-
ogists prescribe higher MTX doses off-label [24, 27]. It
is remarkable that such low-dose MTX potentiates toc-
ilizumab action in severe RA patients. The differences in
baseline characteristics between patients who did and did
not concomitantly receive MTX may have accounted for
this result, since patients who received MTX had a longer
disease duration, higher disease activity, and lower usage
of anti-TNF therapies. It is likely that tocilizumab was
prescribed in combination with MTX in patients who had a
lower risk of adverse events and as monotherapy in patients
with a higher risk. Due to the observational nature of this
study, safety issues associated with combined tocilizumab/
MTX were not sufﬁciently evaluated; however, consider-
ing the high retention rate (Fig. 4) and laboratory proﬁles
(Table 2) associated with tocilizumab therapy with or
without MTX, the addition of MTX does not appear to
signiﬁcantly increase the risk of adverse events. As the
Fig. 3 Efﬁcacy of tocilizumab
infusion in inhibiting the signs
and symptoms of RA patients
seen in daily clinical practice.
Disease activity as assessed by
DAS28 values at baseline and
after 24 weeks of tocilizumab
therapy is shown: a all 229 cases,
b patients who concomitantly
received MTX (n = 127),
c patients who did not
concomitantly receive MTX
(n = 102), d patients who
previously received anti-TNF
therapy (n = 144), e patients
who did not previously receive
anti-TNF therapy (n = 85).
Disease activity was categorized
ashigh(DAS28[5.1),moderate
(3.2 B DAS28 B 5.1), low
(2.6 B DAS28\3.2) and
remission (DAS28\2.6) from
the top column. Data were
analyzed by the LOCF method
128 Mod Rheumatol (2011) 21:122–133
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123addition of MTX to the therapeutic regimen may enhance
the efﬁcacy of tocilizumab, concomitant use of MTX is
recommended with tocilizumab therapy in patients in
whom safety is not a concern.
An interesting ﬁnding was the lack of any differences in
tocilizumab efﬁcacy in patients who did or did not previ-
ously receive anti-TNF therapy, suggesting that clinical
response to tocilizumab therapy is independent of the prior
use of anti-TNF agents. This result is inconsistent with
the report of Nakashima et al. [25], in which the authors
reported a higher efﬁcacy of tocilizumab in biologic naı ¨ve
patients. It is highly possible that the deﬁnition of MTX-
refractory or anti-TNF refractory differs between rheuma-
tologists. Although the baseline DAS28-ESR values in our
study (5.7) and that of Nalashima et al. (5.5) were com-
parable, the average dose of MTX at baseline was higher in
our study (8.7 ± 3.1 vs. 6.8 ± 2.1 mg/week). This higher
dose means that the deﬁnition of MTX-refractory was more
stringent in our study than in that of Nakashima et al. and
that our RA patients had more active disease. It is
reasonable to assume that the severity of RA in patients
would affect the clinical outcome after tocilizumab
therapy.
Clinical data on rituximab and abatacept demonstrate
that both of these agents reduce disease activity in patients
with inadequate responses to anti-TNF therapy. However,
the remission rates of these non-TNF biologic agents in
anti-TNF-naı ¨ve or -refractory populations differ. For
abatacept, the remission rate in MTX-resistant patients
(AIM study) was 14.8% [28], while that in anti-TNF
therapy-refractory patients (ATTAIN study) was 10.0%
[29]. In the case of rituximab, the American College of
Rheumatology (ACR) 70% rate in MTX-resistant patients
(DANCER study) was 20% [30], and that in anti-TNF
therapy-refractory patients (REFLEX study) was 12% [31].
In contrast to rituximab and abatacept, remission rates
observed in tocilizumab clinical studies were quite similar
between MTX-resistant patients (OPTION, 27% [17];
TOWARD, 30% [32]) and anti-TNF therapy-refractory
patients (RADIATE, 30% [33]). Although it may not be
Fig. 4 Kaplan–Meier curve of
the retention rate of tocilizumab
therapy. a Tocilizumab
retention rate in all 229 cases.
b Tocilizumab retention rates by
cause of discontinuation.
c Tocilizumab retention rates in
patients who did (n = 127) and
did not (n = 102) receive
concomitant MTX.
d Tocilizumab retention rates in
patients who did (n = 144) and
did not (n = 85) previously
receive anti-TNF therapy
130 Mod Rheumatol (2011) 21:122–133
123appropriate to compare the results of clinical trials con-
ducted in these different patient population, it is interesting
to realize that the results from tocilizumab clinical studies
have been fairly consistent despite the patient population.
TNF is widely accepted as an important cytokine [4],
and it is known to induce IL-6 activity [34, 35]; however,
IL-6 activity is not totally dependent on TNF stimulation
[1, 36, 37]. The results of our study also suggest that toc-
ilizumab has mechanisms of action that are unique from
those of anti-TNF agents. As such, TNF represents an
important therapeutic option for anti-TNF agent non-
responders as well as disease-modifying antirheumatic
drug (DMARD) non-responders.
In an attempt to identify predisposing factors for toc-
ilizumab efﬁcacy, we analyzed factors associated with
remission using the demographic characteristics of our RA
patients as the explanatory variables for logistic regression.
The results of this analysis revealed that a low DAS28 at
baseline and a younger age were associated with the
induction of remission. Although patients at an earlier
disease stage have been reported to be more sensitive to
anti-rheumatic treatments [38], disease duration in our
study did not appear to be correlated with remission. Since
this study was conducted as a retrospective analysis of data
collected in daily practice, many confounding factors could
have potentially inﬂuenced the data. However, considering
the high remission rate observed in the SAMURAI study
(59%) [16], which was conducted in early RA patients in
Japan, tocilizumab may prove to be most efﬁcacious in
younger patients and/or in those with early-stage disease.
Since IL-6 has pleiotropic actions, some of which are
inconsistent with TNF actions, the inhibition of IL-6 action
by tocilizumab may cause unexpected adverse reactions.
Thus, the safety proﬁle associated with tocilizumab needs
to be carefully evaluated. With respect to laboratory
parameters, decreased WBC counts and increased liver
enzyme levels and/or serum cholesterol levels have been
reported to be associated with tocilizumab use [15, 39].
However, in our study, although signiﬁcant WBC count
decreases and AST/ALT and TC increases were observed,
these changes were tolerable (Table 2). Only two patients
discontinued tocilizumab due to hepatic disorders (Table 3),
and the liver enzyme levels returned to normal after the
discontinuation of tocilizumab therapy. Interestingly, liver
enzyme levels signiﬁcantly increased in patients who con-
comitantly received MTX, but not in those who did not
receive MTX, which is consistent with the ﬁndings of pre-
vious studies [16, 17, 32, 33]. Among 47 patients who dis-
continued tocilizumab, 12 did so due to insufﬁcient efﬁcacy,
while 26 discontinued because of adverse events. Among the
latter, six patients discontinued due to pneumonia. Pneu-
monia was the most frequent adverse event observed in
previous Japanese post-marketing surveillance (PMS) eval-
uation of inﬂiximab [40] and etanercept [27], which is
consistent with the results of our study. However, it should
be noted that susceptibility to infection is an important
concern not only in association with anti-TNF therapies but
also with the anti–IL-6 activity of tocilizumab.
The safety proﬁle of tocilizumab therapy was recently
extensively investigated in Japan using an all-case regis-
tered PMS study conducted by Chugai Pharmaceutical
under the auspices of the regulatory authority of the Japanese
government, with effective suggestions from the subcom-
mittee of the Japan College of Rheumatology. A total of
9,000 cases were registered from April 2008 to December
2009, and an interim analysis is currently being conducted.
Theﬁnalanalysisisexpectedtodescribethesafetyproﬁleof
and risk factors associated with tocilizumab therapy on a
large scale.
In conclusion, this REACTION study conﬁrmed the
efﬁcacy of tocilizumab in Japanese patients with RA.
Tocilizumab was also well tolerated, and the retention rate
at 24 weeks was 79.5%. The promising efﬁcacy of toc-
ilizumab in improving measures of disease activity and
preventing progression of this disabling disease has
allowed this agent to become one of the critical advances in
the management of RA in recent years. The present data
should facilitate a more efﬁcacious use of this expensive
biological agent in daily rheumatology practice, not only in
Japan but also in many countries throughout the world.
Table 3 Cause of tocilizumab discontinuation
Cause of discontinuation Number of cases/events
Lack of efﬁcacy 12 cases (5.2%)
Adverse events 26 cases (11.4%)
Pneumonia 6
Heart failure 3
Worsening comorbidity 3
Liver damage 2
Interstitial pneumonia 2
Skin ulcer 2
Cerebellar hemorrhage 2
Anaphylaxis 1
Chest pain 1
Myocardial infarction 1
Leukopenia 1
Breast cancer 1
Phlegmon 1
Miscellaneous 9 cases (3.9%)
Unknown 4
Moving 3
Patient’s will 2
Total 47 cases (20.5%)
Mod Rheumatol (2011) 21:122–133 131
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